Skip to main content
. Author manuscript; available in PMC: 2013 Feb 15.
Published in final edited form as: Cancer Res. 2011 Dec 28;72(4):887–896. doi: 10.1158/0008-5472.CAN-11-2637

Figure 1.

Figure 1

BTLA is upregulated and co-expressed with PD-1 and Tim-3 on NY-ESO-1-specific CD8+ T cells. (A) Pooled data from eleven melanoma patients showing the percentage (%) and MFI of BTLA expression on NY-ESO-1-specific, MART-1-specific, virus-specific and total CD8+ T cells. (B) Dot plots from one representative melanoma patient showing ex vivo BTLA, PD-1 and Tim-3 expression on NY-ESO-1-specific CD8+ T cells. Values indicate the percentage of CD8+ T cells that express PD-1 and/or BTLA among tet+ CD8+ T cells and express Tim-3 within different subsets of tet+ CD8+ T cells defined by BTLA and PD-1 expression. (C) Pooled data from eleven melanoma patients showing the distribution of NY-ESO-1-specific, virus-specific and total CD8+ T cells according to BTLA, PD-1 and Tim-3 expression. Horizontal bars depict the mean percentage or MFI of BTLA and/or PD-1 and/or Tim-3 expression on tet+ CD8+ T cells. Data shown are representative of two independent experiments.